Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

February 27, 2024

https://www.globenewswire.com/news-release/2024/02/27/2835781/0/en/Greenwich-LifeSciences-Flamingo-01-Phase-III-Clinical-Trial-Approved-to-Expand-into-Five-Largest-European-Countries.html

STAFFORD, Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) — Greenwich LifeSciences, Inc. (Nasdaq:GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the expansion of the clinical trial into Europe.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.